KR850005417A - 화학적 화합물 - Google Patents

화학적 화합물 Download PDF

Info

Publication number
KR850005417A
KR850005417A KR1019850000179A KR850000179A KR850005417A KR 850005417 A KR850005417 A KR 850005417A KR 1019850000179 A KR1019850000179 A KR 1019850000179A KR 850000179 A KR850000179 A KR 850000179A KR 850005417 A KR850005417 A KR 850005417A
Authority
KR
South Korea
Prior art keywords
methyl
formula
compound
dihydro
phenyl
Prior art date
Application number
KR1019850000179A
Other languages
English (en)
Other versions
KR920006781B1 (ko
Inventor
앤토니 슬래터 로버트
Original Assignee
데비드 마틴 워터스
스미스 클라인 앤드 프랜취 라보라토리스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데비드 마틴 워터스, 스미스 클라인 앤드 프랜취 라보라토리스 리미티드 filed Critical 데비드 마틴 워터스
Publication of KR850005417A publication Critical patent/KR850005417A/ko
Application granted granted Critical
Publication of KR920006781B1 publication Critical patent/KR920006781B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

화학적 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. R1이 수소 또는 메틸이고 R2가 수소 또는 C1-4알킬로서 다음 공정을 포함하는 다음 일반식(Ⅰ)화합물 또는 그 약학적으러 허용 가능한 염을 제조하는 방법.
    (가) R1이 앞서 정의한 바와 같은 다음 일반식(Ⅲ)화합물을,
    L1이 이탈그룹이고 R은 R2가 앞서 정의한 바와 같은 NHR2그룹이거나 R이 이탈그룹 L2인 일반식(Ⅳ)화합물과 반응시키고 ;
    그 후에 R이 이탈그룹 L2면 R2가 앞서 정의한 바와 같은 아민 NH2R2와 반응시키거나 또는 (나)일반식 (Ⅴ)화합물을,
    L2, R1및 RR가 앞서 정의한 바와 같은 아민 NH2R2와 반응시키거나; 또는 (다) R1과 R2가 앞서 정의한 바와 같고 X는 치환 가능한 그룹인 일반식(Ⅵ)화합물을,
    하이드라진 또는 그 화학적 균등률과 반응시키거나; 또는 (라) R1과 R2가 앞서 정의한 바와 같고, A는 치환가능 그룹인 일반식(Ⅶ)화합물을,
    시안아마이드 또는 그것들의 중금속염과 반응시키거나; (마) R2가 수소인 일반식(Ⅰ) 화합물을 얻기 위해, 앞서 정의한 일반식(Ⅲ) 화합물을 디시안아마이드염과 반응시키고; 그 후 약학적으로 허용가능한 이들의 염을 임의로 형성시키는 것으로 구성되는 상기 제조방법.
  2. 청구범위 1에서 일반식(Ⅳ) 화합물의 L1과 L2가 독립적으로 벤질티오, C1-6알킬리오, C1-6알콜시, 페녹시 또는 벤젤톡시인 공정.
  3. 청구범위 1에서 일반식(Ⅴ) 화합물의 L2벤젤티오, C1-6알킬리오, C1-6알콕시, 페녹시 또는 벤질톡시인 공정.
  4. 청구범위 1에서 일반식(Ⅵ) 화합물의 X가 하이드록시, C1-6알콕시, 아미노 또는 C1-6알킬아미노인 공정.
  5. 청구범위 1에서 일반식(Ⅶ) 화합물의 A가 메르캅토, C1-4알킬티오, C1-4알콕시, 페녹시 또는 벤질톡시인 공정.
  6. 청구범위 1내지 5중에서 R1이 메틸인 화합물을 제조하기 위한 공정.
  7. 청구범위 1내지 6중에서 R2가 C1-4알킬인 화합물의 제조를 위한 공정.
  8. 청구범위 7에서 R2가 메틸 또는 에틸인 화합물의 제조를 위한 공정.
  9. 청구범위 1에서 다음 화합물의 제조를 위한 공정 :
    6-[4-(N3-메틸-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온,
    6-[4-(N3-에틸-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온,
    6-[4-(N3-이소프로필-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온,
    6-[4-(N3-부틸-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온,
    6-[4-(N3-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온, 또는 6-[4-(N3-메틸-N2-시아노구아니디노)페닐]-4,5-디하이드로-3(2H)-피리다진.
  10. 6-[4-(N-시아노S-메틸이소티오우레이도)페닐)-5-메틸-4,5-디하이드로-3(2H)-피리다진온과 메틸아민과의 반응을 포함하는 6-[4-(N3-메틸-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온을 제조하는 공정.
  11. 6-(4-[N2-시아노)페녹시포름아미디노)]페닐)-5-메틸-4,5-디하이드로-3(2H)-피리다진온과 메틸아민과의 반응을 포함하는 6-[4-(N3-메틸-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온을 제조하는 공정.
  12. 일반식(Ⅰ) 화합물 또는 약학적으로 바람직한 그 염과 약학적으로 바람직한 전달체를 결합시키는 공정을 포함하는 약학적인 성형을 제조하는 공정.
  13. 청구범위 12에서 일반식(Ⅰ)화합물이 6-[4-(N3-메틸-N2-시아노구아니디노)페닐]-5-메틸-4,5-디하이드로-3(2H)-피리다진온 공정.
  14. R1과 L2가 청구범위 1에서 정의한 바와 같은 다음 일반식(Ⅴ) 화합물을 제조하는 공정 :
    (가)R1이 앞서 정의한 바와 같은 다음 구조식(Ⅲ) 화합물을,
    L1과 L2가 청구범위 1에서 정의한 바와 같은 다음 구조식으 화합물과 반응시킴, 또는
    (나) L2,X 및 R1이 청구범위 1에서 정의한 바와 같은 다음 구조식의 화합물을,
    하이드라진 또는 그 화학적 동질물과 반응시킴.
  15. 청구범위 14에서 R1이 메틸이고, L2가 페녹시, C1-6알콕시 또는 C1-6알칼티오인 화합물의 제조를 위한 공정.
  16. 청구범위 15에서 L2가 메틸티오인 화합물의 제조를 위한 공정.
  17. 청구범위 15에서 에톡시인 화합물의 제조를 위한 공정
  18. R1과 L2가 청구범위 1에서 정의한 바와 같은 다음 일반식(Ⅴ) 화합물,
  19. R1과 R2및 X가 청구범위 1에서 정의한 바와 같은 다음구조식(Ⅵ) 화합물 :
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850000179A 1984-01-13 1985-01-12 디하이드로 피리다진온 유도체를 제조하는 방법 KR920006781B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds
GB8400863 1984-01-13

Publications (2)

Publication Number Publication Date
KR850005417A true KR850005417A (ko) 1985-08-26
KR920006781B1 KR920006781B1 (ko) 1992-08-17

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850000179A KR920006781B1 (ko) 1984-01-13 1985-01-12 디하이드로 피리다진온 유도체를 제조하는 방법

Country Status (31)

Country Link
US (1) US4654342A (ko)
EP (1) EP0150937B1 (ko)
JP (3) JPS60158181A (ko)
KR (1) KR920006781B1 (ko)
CN (1) CN85101722A (ko)
AT (1) ATE37179T1 (ko)
AU (1) AU572252B2 (ko)
CA (2) CA1251209A (ko)
CS (1) CS248731B2 (ko)
DD (1) DD231350A5 (ko)
DE (1) DE3564941D1 (ko)
DK (1) DK162519C (ko)
ES (3) ES8607949A1 (ko)
FI (1) FI850140L (ko)
GB (1) GB8400863D0 (ko)
GR (1) GR850068B (ko)
HU (1) HU193591B (ko)
IE (1) IE57969B1 (ko)
IL (1) IL74031A (ko)
JO (1) JO1351B1 (ko)
MY (1) MY100124A (ko)
NO (1) NO850129L (ko)
NZ (1) NZ210816A (ko)
PH (1) PH22136A (ko)
PL (1) PL147123B1 (ko)
PT (1) PT79819B (ko)
RO (1) RO92607A (ko)
SU (1) SU1396963A3 (ko)
WO (1) WO1985003076A1 (ko)
ZA (1) ZA85251B (ko)
ZW (1) ZW385A1 (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US6562821B2 (en) 2001-02-27 2003-05-13 Mitokor Aryl-N-cyanoguanidines and methods related thereto
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
CA2629367C (en) * 2005-11-14 2016-05-03 Boehringer Ingelheim Vetmedica Gmbh Use of pde iii inhibitors and/or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR20110089851A (ko) 2008-11-25 2011-08-09 베링거잉겔하임베트메디카게엠베하 비대 심근병증의 치료를 위한 포스포디에스테라제 타입 Ⅲ（ＰＤＥ Ⅲ） 억제제 또는 Ｃａ２＋―감작제
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
KR102455648B1 (ko) 2013-07-19 2022-10-19 베링거잉겔하임베트메디카게엠베하 보존된 에테르화된 사이클로덱스트린 유도체 함유 액체 수성 약제학적 조성물
IL280864B2 (en) 2013-08-09 2024-03-01 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
EP0030835B1 (en) * 1979-12-05 1983-05-11 Morishita Pharmaceutical Co. Ltd. Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
EP0059688B1 (de) * 1981-03-04 1985-05-15 Ciba-Geigy Ag Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants

Also Published As

Publication number Publication date
PT79819A (en) 1985-02-01
KR920006781B1 (ko) 1992-08-17
HUT37128A (en) 1985-11-28
CA1260471C (ko) 1989-09-26
ATE37179T1 (de) 1988-09-15
GR850068B (ko) 1985-05-03
PL251516A1 (en) 1985-12-17
ZW385A1 (en) 1985-08-07
ZA85251B (en) 1986-08-27
PL147123B1 (en) 1989-04-29
ES549629A0 (es) 1987-03-01
EP0150937B1 (en) 1988-09-14
IE850069L (en) 1985-07-13
EP0150937A3 (en) 1985-08-21
AU3761185A (en) 1985-07-18
RO92607A (ro) 1987-11-30
CN85101722A (zh) 1987-01-31
JPS60158181A (ja) 1985-08-19
DK162519C (da) 1992-03-30
HU193591B (en) 1987-11-30
NO850129L (no) 1985-07-15
DE3564941D1 (en) 1988-10-20
JPS63313775A (ja) 1988-12-21
CA1251209A (en) 1989-03-14
US4654342A (en) 1987-03-31
NZ210816A (en) 1987-06-30
JPS63313776A (ja) 1988-12-21
GB8400863D0 (en) 1984-02-15
MY100124A (en) 1989-12-18
IL74031A0 (en) 1985-04-30
CA1260471A (en) 1989-09-26
IL74031A (en) 1988-07-31
ES539446A0 (es) 1986-06-01
EP0150937A2 (en) 1985-08-07
IE57969B1 (en) 1993-06-02
CS248731B2 (en) 1987-02-12
WO1985003076A1 (en) 1985-07-18
SU1396963A3 (ru) 1988-05-15
AU572252B2 (en) 1988-05-05
DK9185D0 (da) 1985-01-08
ES554965A0 (es) 1987-07-01
DK162519B (da) 1991-11-11
ES8607949A1 (es) 1986-06-01
DD231350A5 (de) 1985-12-24
DK9185A (da) 1985-07-14
PT79819B (en) 1987-01-07
FI850140L (fi) 1985-07-14
PH22136A (en) 1988-06-01
JO1351B1 (en) 1986-11-30
FI850140A0 (fi) 1985-01-11
ES8703846A1 (es) 1987-03-01
ES8706645A1 (es) 1987-07-01

Similar Documents

Publication Publication Date Title
KR850005417A (ko) 화학적 화합물
KR830007685A (ko) 세팔로스포린 유도체의 제조방법
ATE47998T1 (de) Antiinflammatorische phthalazinone.
KR830002757A (ko) 피리미딘 화합물의 제조방법
KR840006212A (ko) 2-치환페닐-4, 5, 6, 7-테트라하이드로-2h-인다졸류의 제조방법
KR890005111A (ko) 아미디노 트리사이클 유도체
KR860001796A (ko) α-아릴-4-(4,5-디히드로-3,5-디옥소-1,2,4-트리아진-2(3H)-일) 벤젠아세토니트릴의 제조방법
KR910007898A (ko) 나프틸옥사졸리돈 유도체
KR850005827A (ko) 2-치환페닐-3-클로로테트라히드로-2h-인다졸류의 제조방법
GB1189769A (en) Triazine Derivatives, processes for their manufacture and use
KR840001948A (ko) 치환된 하이드록 시-말론산 디아미드의 제조방법
KR840001141A (ko) 치환된 아졸일-페녹시 유도체의 제조방법
KR850001907A (ko) 구충제 화화물 및 조성물의 제조방법
EP0158020B1 (en) Process for preparing 2-hydrazino-1,3-diazacycoalk-2-ene hydrohalides
KR940005586A (ko) 피리다지논 유도체 및 그의 제조방법
KR900006308A (ko) 중추 신경계에 작용하는 치환된 방향족 화합물
KR100273823B1 (ko) 5-치환된 사이토신 및 다른 4,5-이치환된 피리미딘-2(1h)-온의 제조방법
KR890006617A (ko) 벤즈 이미다졸과 그 제법 및 이를 함유하는 약학적 제제
KR840004089A (ko) 구아니디노 헤테로사이클릭페닐아미딘의 제조방법
KR860001060A (ko) 시클로헥세논 유도체의 제조방법
KR870003087A (ko) 페녹시프탈리드 유도체, 그 제조방법 및 이를 함유하는 제초 조성물
KR880013879A (ko) 신규한 페녹시 아닐리드 화합물
KR840006331A (ko) 벤조알우레아 화합물의 제조방법
KR910018354A (ko) 2-아미노-4-트리클로로피리딘 유도체
ES8505973A1 (es) Un procedimiento para la preparacion de derivados de pirimidinatriona

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee